Phase: Phase III
Type: Treatment
Status: Active
Age: Under 50
Sponsor: NCI, Other
Protocol IDs: CDR0000068608, EURO-EWING-INTERGROUP-EE99, EBMT-INTERGROUP-EE99, EORTC-62981, GPOH-AUSTRIA-INTERGROUP-EE99, GPOH-GERMANY-INTERGROUP-EE99, SFOP-INTERGROUP-EE99, SWS-SAKK-INTERGROUP-EE99, CCLG-INTERGROUP-EE99, COG-AEWS0331, EU-20213, AEWS0331, NCT00020566

Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 2 to 21
Sponsor: NCI
Protocol IDs: SCUSF-0703, MCC-0703, SCUSF 0703, NCT01132547

Phase: Phase III
Type: Treatment
Status: Active
Age: 6 months to 21 years
Sponsor: Other
Protocol IDs: CWS-2007-HR, 4033024 (BfArM), 293/2007AMG1 (Ethikkommission), 2007-001478-10, A2007/14 (Kinderkrebsstiftung), 498 (Krebsstudienregister), NCT00876031

Phase: Phase III
Type: Treatment
Status: Active
Age: 4 to 50
Sponsor: Other
Protocol IDs: 108128, EudraCT number: 2008-003658-13, NCT00987636

Phase: Phase III
Type: Diagnostic
Status: Active
Age: 2 to 18
Sponsor: Other
Protocol IDs: 1000010635, NCT00751920

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 50 and under
Sponsor: NCI, Other
Protocol IDs: CDR0000687639, COG-AEWS1031, AEWS1031, NCT01231906

Phase: Phase III
Type: Educational/Counseling/Training, Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UHN REB 09-0855-C, CIHR, NCT01506492

Phase: Phase III
Type: Educational/Counseling/Training, Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Lenze-2011, NCT01631175

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ISG-STS 10-01, NCT01710176

Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 18
Sponsor: Other
Protocol IDs: CCHE-BoneT002, NCT01734863

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: ECP RIT, NCT00179790

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: BMT 0499 Solid, NCT00179816

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AVF4761s, 200911736, NCT01106872

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01412, 10-049, CDR0000680558, MSKCC-10049, U01CA069856, 8406, NCT01154452

Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 3 to 75
Sponsor: Other
Protocol IDs: NDV-HUJ-HMO-CTIL, NCT01174537

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 20
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: 100220, IND 59,056, NCT01222780

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: Other
Protocol IDs: 2010-0700, NCT01590069

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 and over
Sponsor: NCI
Protocol IDs: 120135, 12-C-0135, NCT01610570

Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: PSCI-2003-232, NCT00084695

Phase: Phase II
Type: Treatment
Status: Active
Age: 25 and under
Sponsor: Other
Protocol IDs: RTSARC, NCT00186992

Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 25
Sponsor: Other
Protocol IDs: NAVE-CYCLO, NCT00180947

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965

Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: 05-326, Other, NCT00592293

Phase: Phase II
Type: Treatment
Status: Active
Age: 2 to 17
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO20924, 2007-005017-19, NCT00643565

Phase: Phase II
Type: Treatment
Status: Active
Age: 12 to 70
Sponsor: Other
Protocol IDs: 0457-08-HMO-CTIL, NCT00855452